1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Orient Europharma Co., Ltd.

Orient Europharma Co., Ltd.

TTPEX:4120
44.75
TWD
-0.35
(-0.78%)
-5.46EPS
3.95BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
53.78
57.64
56.57
60.31
60.25
63.52
70.24
62.06
54.95
54.53
52.93
50.62
52.97
53.77
Basic EPS, GAAP
5.84
2.26
2.57
5.41
5.29
2.84
2.86
2.3
1.39
-3.58
1.66
-3.27
-6.54
-6.66
Free Cash Flow per Basic Share
-1.36
1.81
4.73
-1.31
2.66
0.31
0.56
4.3
-17.18
-9.91
-0.42
-2.55
-5.54
-9.77
Dividend per Share
2.02
1.83
1.73
1.97
1.92
2.62
1.95
1.86
1.63
1
0.18
1.16
1.16
1.06
Book Value per Share
32.93
32.64
33.33
36.25
37.67
37.84
36.83
36.99
33.91
33.76
40.51
59.53
72.48
60.28
Tangible Book Value per Share
31.95
31.65
32.32
35.26
36.7
36.85
35.4
35.78
33.01
33.27
40.02
59.03
71.89
59.7
Basic Weighted Avg Shares
87
87
87
87
87
87
87
87
87
87
87
87
87
87
Sales/Revenue/Turnover
4,665
5,000
4,907
5,232
5,226
5,510
6,093
5,384
4,767
4,730
4,592
4,391
4,595
4,653
Operating Margin (%)
1.41
4.27
5.37
9.05
8.33
6.48
5.43
2.18
-2.06
-3.17
1.57
0.3
-6.5
-7.26
Depreciation Expense
86
97
109
109
96
104
182
197
191
194
216
207
198
197
Net Income, GAAP
507
196
223
470
459
247
248
199
120
-311
144
-284
-567
-576
Effective Tax Rate (%)
0.89
43.64
33.74
17.77
36.42
60.1
62.53
57.23
12.35
- -
33.94
- -
- -
- -
Profit Margin (%)
10.86
3.92
4.55
8.98
8.78
4.48
4.06
3.7
2.52
-6.57
3.13
-6.47
-12.35
-12.38
Working Capital
1,744
1,693
1,549
2,202
1,798
2,251
1,769
1,888
693
392
515
668
1,383
556
LT Debt
323
234
320
766
372
723
851
988
1,899
2,439
2,203
1,698
1,233
1,233
Total Equity
3,517
3,418
3,384
3,916
4,098
4,142
3,812
3,905
3,453
3,444
4,162
5,824
7,354
6,339
Return on Invested Capital (%)
2.51
3.01
4.3
8.43
5.53
2.62
2.18
0.79
1.03
- -
0.53
- -
- -
- -
Return on Capital (%)
15.57
6.64
7.87
12.28
11.57
6.59
6.4
4.99
2.85
- -
2.16
- -
- -
- -
Return on Common Equity (%)
19.28
6.89
7.8
15.56
14.31
7.53
7.65
6.23
3.91
-10.59
4.47
-6.54
-9.91
-10.08

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,037
2,144
2,293
LT Borrowings
925
903
925
LT Finance Leases
308
310
307
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
87
87
Market Capitalization
3,886
4,025
3,951

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,298
4,036
4,036
Cash, Cash Equivalents & STI
2,122
1,876
1,546
Accounts Receivable, Net
767
726
740
Inventories
1,086
1,063
1,223
Total Current Liabilities
2,915
2,923
3,480
Payables & Accruals
- -
- -
- -
ST Debt
2,037
2,144
2,293
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.11%
15.04%
26.25%
Free Cash Flow
22.36%
-1.12%
117.28%
Net Income, GAAP
-69.93%
-148.41%
99.83%
Sales/Revenue/Turnover
-0.4%
-2.98%
4.64%
Total Cash Common Dividend
43.29%
83.05%
0.07%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,104
1,086
1,067
1,134
4,391
2025
1,156
1,126
1,115
1,197
4,595
2026
1,151
1,189
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
-0.81
0.13
-1.56
-3.27
2025
-1.77
-0.53
-1.49
-2.76
-6.54
2026
-0.29
-2.11
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.99
0.06
1.16
2025
- -
- -
1
0.06
1.16
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mon Lin Tsai
Full Time Employees
339
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 128, Chengde Road Taipei TP Taiwan 112052
IPO Date
Nov 28, 2002
Website
oep.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Orient EuroPharma Co., Ltd. (4120.TWO) is a multinational pharmaceutical company that develops, manufactures, markets, and distributes prescription medicines, nutritional care products, dermo-cosmetics, healthcare supplements, and innovative medical therapies across Asia-Pacific markets including Taiwan, Singapore, Malaysia, Hong Kong, Macau, the Philippines, mainland China, and Indonesia. Its prescription medicines encompass cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, oncology, and anti-cancer drugs sourced from international partners; nutrition and baby care offerings include goat milk formulas and nutritional supplements under the Karihome, Babecare, and Ostricare brands; dermo-cosmetics feature skincare products such as essences, creams, lotions, eye creams, and body treatments under AGLab, Bio-Oil, Buccotherm, ISISPHARMA, and Mister Baby brands; healthcare supplements target preventive medicine for aging populations; and innovative medical products involve R&D pipelines like Multikine for head and neck cancer, NC-6004 for chemotherapy, ASC-J9 for androgen degradation, and 2ccPA for osteoarthritis. Founded in 1982 and headquartered at 13F, No. 128, Sec. 6, Chengde Road, Taipei, Taiwan, the company listed on the Taipei Exchange in 2003 and operates subsidiaries including Orient Pharma for R&D and manufacturing, OP NanoPharma, and overseas entities in Southeast Asia and China. In recent developments, Orient EuroPharma, through affiliate Cyntec, signed an exclusive licensing agreement with Rakuten Medical in June 2025 for Alluminox platform-based photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines to expand its oncology portfolio; its subsidiary Orient Pharma plans an OTC market listing in late August 2025 following achievements in international certifications; and earlier partnerships include a 2024 commercial license for Trogarzo with Taimed Biologics in Taiwan and a 2023 license for oregovomab with OncoVent for ovarian cancer in the region.

Company News

Company News APIChatGPT

  • globenewswire.com

    George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia